Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1485529 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CA1CA2CA9CA14 | |
| SCHEMBL31154018 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CA1CA2CA9CA14 | |
| SCHEMBL5698807 | 0.80 | CA2 (0.35) | ALDH1A1CA1CA2CA9CA14 | |
| SCHEMBL2781939 | 0.77 | ALDH1A1 (0.50) | ALDH1A1CA1CA2CA9CA14 | |
| SCHEMBL14339239 | 0.77 | ALDH1A1 (0.50) | ALDH1A1CA1CA2CA9CA14 | |
| SCHEMBL4371933 | 0.77 | ALDH1A1 (0.50) | ALDH1A1CA1CA2CA9CA14 | |
| SCHEMBL3441094 | 0.77 | ALDH1A1 (0.50) | ALDH1A1CA1CA2CA9CA14 | |
| SCHEMBL23224409 | 0.76 | ALDH1A1 (0.44) | ALDH1A1CA1CA2CA9CA14 | |
| SCHEMBL9590966 | 0.75 | ALDH1A1 (0.48) | ALDH1A1USP2TSHR | |
| SCHEMBL9591753 | 0.75 | ALDH1A1 (0.48) | ALDH1A1USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024220399-A1 | PYRAZOLOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-24 | — | — | WO | disclosed |
| US-10550125-B2 | Prodrugs of imidazotriazine compounds as CK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180305364-A1 | PRODRUGS OF IMIDAZOTRIAZINE COMPOUNDS AS CK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305364-A1 | PRODRUGS OF IMIDAZOTRIAZINE COMPOUNDS AS CK2 INHIBITORS | CSNK2A1, CSNK1A1, CSNK2A2 | ALDH1A1 2768/4885CA1 236/4885CA2 98/4885 |
| US-10550125-B2 | Prodrugs of imidazotriazine compounds as CK2 inhibitors | CSNK1A1, CSNK2A1, CSNK2A2 | ALDH1A1 2268/4885CA1 300/4885CA2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.